Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 741 | 965 | 311 | 629 | 1,269 |
| Gross Profit | 741 | 965 | 311 | 629 | 1,269 |
| Operating Expenses | 29,102 | 19,532 | 19,554 | 21,192 | 21,400 |
| Operating Income | -28,361 | -18,567 | -19,243 | -20,563 | -20,131 |
| Other Income | -3,120 | 2,889 | 62,374 | -61,560 | 963 |
| Pre-tax Income | -31,481 | -15,678 | 43,131 | -82,123 | -19,168 |
| Income Tax | 56 | 185 | 43 | 27 | 91 |
| Net Income Continuous | -31,537 | -15,863 | 43,088 | -82,150 | -19,259 |
| Net Income | $-31,537 | $-15,863 | $43,088 | $-82,150 | $-19,259 |
| EPS Basic Total Ops | -3.04 | -1.53 | -2.11 | -13.10 | -3.07 |
| EPS Basic Continuous Ops | -3.04 | -1.53 | 5.12 | -13.10 | -3.07 |
| EPS Diluted Total Ops | -3.04 | -1.53 | -2.11 | -13.10 | -3.07 |
| EPS Diluted Continuous Ops | -3.04 | -1.53 | 4.95 | -13.10 | -3.07 |
| EPS Diluted Before Non-Recurring Items | -3.04 | -1.53 | -2.11 | -3.41 | -3.07 |
| EBITDA(a) | $-28,373 | $-18,616 | $-18,870 | $-20,264 | $-19,939 |